A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis by Grayston, R et al.
 Grayston, R, Czanner, G, Elhadd, K, Goebel, A, Frank, B, Uceyler, N, Malik, RA 
and Alam, U
 A systematic review and meta-analysis of the prevalence of small fiber 
pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia 
etiopathogenesis
http://researchonline.ljmu.ac.uk/id/eprint/12147/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Grayston, R, Czanner, G, Elhadd, K, Goebel, A, Frank, B, Uceyler, N, Malik, 
RA and Alam, U (2018) A systematic review and meta-analysis of the 
prevalence of small fiber pathology in fibromyalgia: Implications for a new 
paradigm in fibromyalgia etiopathogenesis. Seminars in Arthritis and 
LJMU Research Online
http://researchonline.ljmu.ac.uk/
Seminars in Arthritis and Rheumatism 48 (2019) 933940
Contents lists available at ScienceDirect
Seminars in Arthritis and Rheumatism
journal homepage: www.elsevier.com/locate/semarthritA systematic review and meta-analysis of the prevalence of small ﬁber
pathology in ﬁbromyalgia: Implications for a new paradigm in ﬁbromyalgia
etiopathogenesisRebecca Graystona, Gabriela Czannera,b, Kareim Elhaddc, Andreas Goebeld, Bernhard Frankd,
Nurcan €Uc¸eylere, Rayaz A Malikf, Uazman Alama,g,h,i*
a Department of Eye & Vision Sciences, Institute of Ageing and Chronic Disease, University of Liverpool and Aintree University Hospital NHS Foundation Trust, Liv-
erpool, UK
b Department of Biostatistics, University of Liverpool, Liverpool, UK
c The Walton Centre NHS Foundation Trust, Liverpool, UK
d The Pain Research Institute, University of Liverpool and The Walton Centre NHS Foundation Trust, Liverpool, UK
eDepartment of Neurology, University of W€urzburg, W€urzburg, Germany
fWeill Cornell Medicine-Qatar, Doha, Qatar
g Diabetes & Endocrinology Research & Pain Research Institute, Department of Eye & Vision Sciences, Institute of Ageing and Chronic Disease, University of Liver-
pool and Aintree University Hospital NHS Foundation Trust, Liverpool, UK
hDepartment of Diabetes and Endocrinology, Royal Liverpool and Broadgreen University NHS Hospital Trust, Liverpool, UK
i Division of Endocrinology, Diabetes and Gastroenterology, University of Manchester, Manchester, UKA R T I C L E I N F O* Corresponding author at: Institute of Ageing & Chr
Centre, University Hospital Aintree, Liverpool L9 7AL, UK
E-mail addresses: uazman.alam@liverpool.ac.uk, Uazm
(U. Alam).
https://doi.org/10.1016/j.semarthrit.2018.08.003
0049-0172/© 2018 The Authors. Published by Elsevier InA B S T R A C T
Objectives: Fibromyalgia is a condition which exhibits chronic widespread pain with neuropathic pain features
and has a major impact on health-related quality of life. The pathophysiology remains unclear, however, there is
increasing evidence for involvement of the peripheral nervous system with a high prevalence of small ﬁber
pathology (SFP). The aim of this systematic literature review is to establish the prevalence of SFP in ﬁbromyalgia.
Methods: An electronic literature search was performed using MEDLINE, EMBASE, PubMed, Web of Science,
CINAHL and the Cochrane Library databases. Published full-text, English language articles that provide SFP
prevalence data in studies of ﬁbromyalgia of patients over 18 years old were included. All articles were
screened by two independent reviewers using a priori criteria. Methodological quality and risk of bias were
evaluated using the critical appraisal tool by Munn et al. Overall and subgroup pooled prevalence were calcu-
lated by random-effects meta-analysis with 95% CI.
Results: Database searches found 935 studies; 45 articles were screened of which 8 full text articles satisﬁed
the inclusion criteria, providing data from 222 participants. The meta-analysis demonstrated the pooled
prevalence of SFP in ﬁbromyalgia is 49% (95% CI: 3860%) with a moderate degree of heterogeneity,
(I2= 68%). The prevalence estimate attained by a skin biopsy was 45% (95% CI: 3259%, I2 = 70%) and for cor-
neal confocal microscopy it was 59% (95% CI: 4078%, I2 = 51%).
Conclusion: There is a high prevalence of SFP in ﬁbromyalgia. This study provides compelling evidence of a
distinct phenotype involving SFP in ﬁbromyalgia. Identifying SFP will aid in determining its relationship to
pain and potentially facilitate the development of future interventions and pharmacotherapy.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license.
(http://creativecommons.org/licenses/by/4.0/)Keywords:
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Fibromyalgia syndrome is characterised by chronic widespread
pain, sleep disturbance, fatigue and cognitive impairment, which
have a major impact on quality of life [1, 2]. Symptoms include tender
and stiff muscles, joints and tendons with multiple tender points,which are often extremely painful to touch [3] without grossly
demonstrable tissue inﬂammation, deformity, or damage [4].
The underlying etiology of ﬁbromyalgia is yet to be fully elucidated.
Dysfunction of the central, autonomic and peripheral nervous systems,
alteration of neurotransmitters, endocrine and immune systems, exter-
nal stressors and psychological aspects have been implicated in the
common symptom of widespread pain in ﬁbromyalgia. There continues
to be debate around the relative contributions of the central nervous
system (CNS) and peripheral nervous system (PNS) in the pathogenesis
of ﬁbromyalgia [5]. Disturbed pain processing with central sensitisation,
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strated in ﬁbromyalgia. Increased central hyperexcitability including
wind up of ascending pathways has been implicated in the generation
of widespread pain in ﬁbromyalgia [6, 7]. A meta-analysis of magnetic
resonance imaging (MRI) based studies (voxel-based morphometry,
functional MRI, or resting state-fMRI) in ﬁbromyalgia showed region-
speciﬁc changes in grey matter volume, a decreased functional connec-
tivity in the descending pain-modulating system, and increased activity
in the pain matrix related to central sensitisation [8]. In addition, single
photon emission computed tomography (SPECT) studies have also
shown decreased regional cerebral blood ﬂow in the caudate and thala-
mus of patients with ﬁbromyalgia compared with matched healthy con-
trols [911]. However, the temporal relationship of CNS pathology and
whether it is a primary defect in ﬁbromyalgia, remains to be established.
Other evidence suggests neurotransmitter abnormalities in ﬁbromyalgia
are central to the development of pain including elevated insular gluta-
mate, abnormal dopamine response to pain and transmission and
metabolism of serotonin leading to dysregulation of pain processing [7,
1216]. Despite these ﬁndings, there is no single unifying CNS pathol-
ogy present in ﬁbromyalgia that deﬁnes this widespread pain state.
While there is no diagnostic gold standard, small ﬁbre neuropathy
(SFN) is currently deﬁned as pain and or par-/or dysesthesias accompa-
nied by ﬁndings of small ﬁbre impairment in at least two of the follow-
ing three tests: neurological examination, quantitative sensory testing,
and skin punch biopsy and exclusion of relevant large ﬁbre neuropathy
[17]. SFN results in selective impairment of unmyelinated C and thinly
myelinated Ad ﬁbers that mediate pain, heat, and cold sensation. There-
fore, pathology of small nerve ﬁbers remains a biologically plausible
explanation that may at least contribute to the ﬁbromyalgia symptom
complex. Indeed, there is a signiﬁcant sensory symptom overlap in
approximately 2035% of patients with painful neuropathy, suggesting
a peripheral neuropathic origin in a subset of people with ﬁbromyalgia
[18]. Fibromyalgia has neuropathic pain features, which is often stimu-
lus dependent with hyperalgesia and also exhibits allodynia often in the
form of burning or prickling sensations; pain attacks are frequently
described [1821]. Decreased detection thresholds for noxious stimuli
such as heat and cold have been demonstrated on quantitative sensory
testing [22, 23]. Phenotypic similarities with other peripheral neuro-
pathic pain disorders suggest the underlying mechanism for these
symptoms may be of small nerve ﬁber origin [24], particularly in a sub-
set of individuals. Recently, reduced intra-epidermal nerve ﬁber (IENF)
density (IENFD) has been demonstrated after a sustained increase in
insular glutamate in an experimental model of ﬁbromyalgia, suggestive
of an underlying pathognomonic neuroplastic process [25]. Several stud-
ies in recent years have demonstrated signiﬁcant small ﬁber pathology
(SFP) in individuals with ﬁbromyalgia [2633], with a reduction in
IENFD [26, 2830, 33]. Other studies have also demonstrated SFP using
corneal confocal microscopy (CCM) [31, 32]. However, SFN needs to be
distinguished from SFP in ﬁbromyalgia as the underlying mechanisms
causing pathology in small ﬁbers remains to be elucidated and the clini-
cal phenotype of ﬁbromyalgia is distinct from SFN [34]. Furthermore, in
a study from the Netherlands the actual prevalence of SFN in the general
population was 52.95 cases (60.9 male/45.4 female) per 100,000 inhabi-
tants [35]. The actual background prevalence of pure SFN is signiﬁcantly
lower [35] than SFP in ﬁbromyalgia [26, 2833].
The aim of this study is to determine the prevalence of SFP in
ﬁbromyalgia through a systematic literature review and meta-analy-
sis of published data which have used an objective assessment of
small nerve ﬁbers.
Methods
Search strategy
In accordance with PRISMA guidelines, protocol for this system-
atic review and meta-analysis was developed and subsequentlyregistered with PROSPERO, (CRD: 42018087277). Electronic literature
searches of MEDLINE (access via OVID), EMBASE (access via OVID),
PubMed, Web of Science, CINAHL and the Cochrane Library were per-
formed for articles reporting ﬁbromyalgia and SFP. The searches were
restricted to English language from inception to April 2018.
A qualiﬁed medical librarian and R.G independently searched the
stated databases using varying combinations of the following search
terms: ‘ﬁbromyalgia’, ‘ﬁbromyositis’, ‘ﬁbrositis’, ‘muscular rheuma-
tism’, ‘musculoskeletal pain syndrome’, ‘nonarticular rheumatism’,
‘periarticular ﬁbrositis’, ‘rheumatoid myositis’, ‘tension myalgia’,
‘myalgia’, ‘small ﬁbre/ﬁber neuropathy’, ‘peripheral neuropathy’, ‘pol-
yneuropathy’, ‘painful neuropathy’, ‘small ﬁbre/ﬁber sensory neurop-
athy’, ‘small ﬁbre/ﬁber pathology’ and ‘neuropathy’.
All the search results were combined using Endnote and dupli-
cates were removed by R.G. Reference lists of the primary and sec-
ondary literature were manually browsed to identify any additional
studies.
Inclusion and exclusion criteria
Studies were included if they (1) were original studies displaying
prevalence data for SFP within a ﬁbromyalgia population, (2) con-
cerned adult patients with ﬁbromyalgia diagnosed in accordance
with international (American College of Rheumatology) ACR diagnos-
tic criteria [3638]; (3) included assessment of small nerve ﬁbers in
all patients, using skin biopsy, corneal confocal microscopy, laser
Doppler imaging (LDI ﬂare), microneurography or quantitative sudo-
motor axon reﬂex testing (QSART) 4) were reported in full-text publi-
cation. Studies were excluded if they, (1) were not a human study, (2)
did not report SFP prevalence within ﬁbromyalgia patients or (3)
were not in English language. Only studies using quantitative struc-
tural or functional measures of small nerve ﬁber integrity were
included within the systematic review as they objectively quantify
small nerve ﬁber deﬁcits. This is in contrast to alternate methods,
which do not localise pathology directly to small nerve ﬁbers i.e. ther-
mal threshold testing. Fibromyalgia was deﬁned in relation to either
the 1990 or 2010 ACR criteria as ‘widespread’ pain, lasting for a
period of 3 months or longer, in association with tender points or
somatic symptoms as described in their respective protocols.
Two reviewers, (R.G. and K.E.) independently screened all articles
and selected those that satisﬁed the inclusion criteria for full text
analysis. The titles and abstracts of articles were screened to remove
irrelevant studies and the remaining shortlisted articles were
screened in depth for eligibility. The full texts of relevant articles
were retrieved, screened and selected using the inclusion and exclu-
sion criteria to compile a set of ﬁnal articles to be reviewed. Both
reviewers made a decision to include or exclude and any discrepan-
cies were put forward to the senior author (U.A.) for ﬁnal judgement
on the inclusion of a study. The process of screening and selection for
inclusion were recorded using a PRISMA ﬂowchart (Fig. 1). Before
data extraction and quality assessment U.A screened all articles in
order to conﬁrm their eligibility within this study.
Data extraction and quality assessment
Study characteristics, methodology data and results from studies
were extracted independently by R.G. and K.E. and any discrepancies
between the R.G. and K.E. were reviewed by U.A. Extraction of the
ﬁrst author, study name and country were completed. Subsequently
followed by the sample size and participant number within each
study group, age, sex, SFP diagnostic technique used, international
guideline of ﬁbromyalgia diagnosis and the prevalence number or
estimation. The combined extracted data was reviewed by U.A. to
ensure accuracy of the data extraction.
The articles were all appraised using a risk of bias tool speciﬁcally
addressing external and internal validity of the selected studies. In
Fig. 2. IENF and CCM images in a healthy volunteer (A, D), a person with ﬁbromyalgia
(B, E) showing SFP and a person with ﬁbromyalgia (C, F) showing no SFP. CCM 
corneal confocal microscopy, IENFD  Intra-epidermal nerve ﬁber density, FM  ﬁbro-
myalgia, SFP  small ﬁber pathology. Permission sought and granted for Fig. 1 from:
€Uc¸eyler N, Sommer C. Small nerve ﬁber pathology. In: Perrot S, Hauser W, eds. Fibro-
myalgia Syndrome and Widespread Pain: From Construction to Relevant Recognition.
Philadelphia, PA. Wolters Kluwer Health; 2019.
Fig. 1. PRISMA ﬂowchart demonstrating the article screening process.
R. Grayston et al. / Seminars in Arthritis and Rheumatism 48 (2019) 933940 935order to evaluate the quality of selected articles, both R.G. and K.E.
independently critically appraised each article using the tool devel-
oped by Munn et al. [39]. This critical appraisal tool assesses the risk
of bias and the methodological practices that may impact the study's
validity [39, 40]. Each article was posed 10 questions; a score of 0 or 1
was recorded representing a ‘yes’ or ‘no’ response respectively deter-
mining confounding, selection bias, bias related to measurement and
data-analysis. A total score was calculated for each article, presenting
their overall risk of bias. A total score between 0 and 3 was consid-
ered low risk, 46 was moderate risk and 7 was high risk of bias.
Any discrepancies in the risk of bias were put forward to the senior
author (U.A.) for a ﬁnal decision.
Description of skin biopsy and CCM
Skin biopsy technique was initially developed at the Karolinska
Institute, Sweden and later standardised at the University of Minne-
sota and at Johns Hopkins University, USA [5]. Skin biopsy analysis of
IENF are used for the diagnosis of patients with SFN through the iden-
tiﬁcation of antibodies against protein gene product 9.5 (PGP 9.5). The
immunoreaction is used to visualize the number and morphology of
the dermal and IENF according to the European Federation of Neuro-
logical Societies (EFNS) [41]. A circular punch biopsy, 35mm in
diameter is rotated into the skin to obtain a cylindrical specimen
which is then ﬁxed, frozen and 50 mm sections are prepared and
immunoreacted with antibodies against PGP 9.5 as a pan-axonal
marker. IENF crossing the dermal-epidermal junction are counted to
provide densities which are referenced against normative ranges to
provide diagnostic cut offs [41].
CCM is a rapid non-invasive ophthalmic imaging modality which
has been recently pioneered as a surrogate endpoint of peripheral
neuropathy. The cornea is the most densely innervated tissue of the
human body and receives sensory innervation from the trigeminal
ganglion in the form of nerve bundles containing axons. These bun-
dles terminate in the anterior cornea where they form a dense net-
work of unmyelinated axons (19,00044,000 axons within 90 mm2
which are small nerve ﬁbers) termed the sub-basal nerve plexus [42].
CCM can image these bundles of axons at 600x magniﬁcation. CCM
quantiﬁes axonal damage in early neuropathy [43], reliably [44], with
high sensitivity and speciﬁcity [45, 46] and closely correlates to the
severity of IENF loss [47, 48[. CCM methodology and assessment may
be viewed in more detail at: http://www.jove.com/index/Details.stp?
ID=2194.We have included comparative images (Fig. 2AC) of IENF in a
healthy-volunteer control, a person with ﬁbromyalgia without SFP
and a person with ﬁbromyalgia and SFP. We have also included CCM
images (Fig. 2DF) of a healthy-volunteer control and people with
ﬁbromyalgia and SFP. This shows SFP as imaged by these two diag-
nostic modalities.
Data analysis
Each article selected for ﬁnal analysis was included within a meta-
analysis to determine the overall prevalence of SFP in ﬁbromyalgia.
Studies were weighted according to the prevalence effect size and
the inverse of the study variance in order to generate an I2 value,
serving as a measure of heterogeneity among the studies. I2 is a mea-
sure of inconsistency within the studies’ results [49] and reports the
percentage of variation amongst studies that is due to heterogeneity
and not chance [50]. The meta-analysis was conducted using a
generic inverse variance outcome. The prevalence estimate of each
study was used as the effect estimate, and the corresponding stan-
dard error (SE) for each study was calculated. The SEs for prevalence
(p) estimates were derived from the equation
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pð1pÞ=np , where n is
the number of participants with completed data in study. Random-
effects model were used to generate summary prevalence data dis-
played (on forest plots) with 95% CIs in view of the higher I2 value
(> 50% for overall pooled data and subgroup analyses). In addition,
individual subgroup forest plots were formed for diagnostic quantita-
tive assessment used in the ﬁnal selected studies. This also enabled
the differences in prevalence estimates between each assessment
method to be observed. A funnel plot was created to show possible
bias within the meta-analysis results (supplementary material).
All statistical analyses and ﬁgure production were under-
taken using Review Manager 5.3 (The Cochrane Collaboration,
London, UK).
Table 1
Data extraction information from all ﬁnal selected studies.
Author Country Sample
size
Study
group
Group
size
Mean age
(years§ SD or range)
Sex
(Female/Male)
SFP diagnostic technique and
criteria for diagnosis
International
ﬁbromyalgia guideline
Prevalence
number
Prevalence
estimate (%)
de Tommaso
et al. [51]
Italy 81 Fibromyalgia
Control
21
60
51§ 9
53§ 6
18/3
50/10
Skin biopsy: IENFD below the 5°
percentile cut-off in the thigh,
distal leg or ﬁnger-tipa
2010 ACR criteria 16 76
Giannoccaro
et al. [28]
Italy 52 Fibromyalgia
Control
20
32
40§ 6
b
19/1
b
Skin biopsy: IENFD below 13.5
ENFs/mm in the thigh or 9.5
ENFs/mm in the distal leg
1990 ACR criteria 6 30
Kosmidis
et al. [30]
Greece 80 Fibromyalgia
Control
46
34
53 (2976)
32 (1984)
41/5
18/16
Skin biopsy: IENFD below 3.65
ﬁbres/mm in the distal leg
2010 ACR criteria 16 34
Leinders
et al. [52]
Germany 116 Fibromyalgia
Control
28
88
51 (3974)
44 (1679)
26/2
80/8
Skin biopsy: IENFD below 6
ﬁbres/mm in the thigh or
distal leg
1990 ACR criteria 14 50
Oaklander
et al. [27]
USA 57 Fibromyalgia
Control
27
30
47 (2668)
45 (2565)
20/7
24/6
Skin biopsy: IENFD below the 5°
percentile cut-off in the distal
lega
2010 ACR criteria 11 41
Oudejans
et al. [31]
Netherlands b Fibromyalgia
Control
39
b
39 (19-58)
b
36/3
b
Corneal confocal microscopy:
CNFD (< 21.3 no/mm2), CNFL
(< 12.7mm/mm2), or CNBD
(< 26.7 no/mm2). Values are
below the 5° percentile cut-
off.
1990 or 2010
ACR criteria
20 51
Ramírez
et al. [32]
Mexico 34 Fibromyalgia
Control
17
17
44§ 5
43§ 6
All female
All female
Corneal confocal microscopy:
CNFD (diagnostic cut-off
unavailable)
1990 or 2010 ACR
criteria
12 71
€Uc¸eyler
et al. [26]
Germany 155 Fibromyalgia
Monopolar depression without pain
Control
24
10
121
59 (5070)
Mean age unknown (3975)
b
22/2
9/1
b
Skin biopsy: IENFD below 8
ﬁbres/mm in the thigh or 6
ﬁbres/mm in the distal leg
1990 ACR criteria 10 42
CNBD  corneal nerve branch density, CNFD  corneal nerve ﬁbre density, CNFL  corneal nerve ﬁbre length, ENF  epidermal nerve ﬁbers, IENFD  intra-epidermal nerve ﬁber density.
a Precise cut-off values for IENFD not provided.
b Information are unavailable.
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Fig. 3. Forest plot showing overall pooled prevalence estimates of SFP in ﬁbromyalgia. de Tommaso et al. [51]; Giannoccaro et al. [28]; Kosmidis et al. [30]; Leinders et al. [52]; Oak-
lander et al. [27]; Oudejans et al. [31]; Ramírez et al. [32] and €Uc¸eyler et al. [26].
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Study characteristics
After the removal of duplicates a total of 935 articles were gener-
ated from the electronic database and manual reference searches. A
PRISMA ﬂowchart was completed displaying the article exclusions at
each stage of screening, (Fig. 1). The titles and abstracts of 45 articles
were screened using the inclusion and exclusion criteria. Analysis of
17 full text articles was performed in order to review eligibility and
inclusion. Overall, eight articles satisﬁed the inclusion criteria and
underwent data extraction (Table 1) and quality assessment (Supple-
mentary material, Table 2).
Six studies were performed in Europe, [26, 28, 30, 31, 51, 52], one
in the USA, [27] and one in Mexico, [32]. Studies had been described
by the authors as case-control, cross-sectional or prospective. All
studies used the 1990 or 2010 [36, 37] ACR Criteria for the classiﬁca-
tion of ﬁbromyalgia as a standard deﬁnition.
Overall prevalence
The meta-analysis evaluated data from all eight articles, providing
eight prevalence estimates; the estimated prevalence ranged
between 30% and 76% (Fig. 3). Forest plot analysis showed the ran-
dom-effects overall prevalence of SFP in ﬁbromyalgia was 49% (95%
CI: 38%, 60%) with a moderately high level of heterogeneity,
(I2 = 68%). Analysis of the overall funnel plot, (Supplementary mate-
rial, Fig. 5) showed an equal but asymmetrical distribution of studies
either side of the overall prevalence estimate.
Subgroup analysis
All selected studies diagnosed small ﬁber pathology in patients
using either a skin biopsy (n = 6) or corneal confocal microscopy
(n = 2). Skin biopsies were undertaken by; de Tommaso et al. [51],
Giannoccaro et al. [28], Kosmidis et al. [30], Leinders et al. [52], Oak-
lander et al. [27] and Uceyler et al. [26]. The six prevalence estimatesFig. 4. Forest plot showing prevalence estimates of SFP in ﬁbromyalgia in studies using skin
et al. [52]; Oaklander et al. [27] and €Uc¸eyler et al. [26].ranged between 30% and 76%, (Fig. 4). Analysis of the skin biopsy
meta-analysis displayed a random-effects pooled prevalence of 45%
(95% CI: 32%, 59%), with a moderately high level of heterogeneity,
(I2 = 70%). In comparison, Oudejans et al. [31] and Ramirez et al. [32]
assessed SFP using corneal confocal microscopy. This meta-analysis,
(Fig. 5) showed the random-effects pooled prevalence was 59% (95%
CI: 40%, 78%), with a moderate heterogeneity, (I2 = 51%).Risk of bias
Evaluation of bias and article quality (Supplementary material,
Table 2) showed the majority of studies had a low risk of bias. The
Giannoccaro et al. [28] study displayed a moderate risk of bias. No
sample size calculation was provided; only 20 ﬁbromyalgia patients
were studied and there were no details of ethnicity or the reasons for
the chosen male/female ratio. Moreover, this study did not explicitly
state a specialist or independent clinician reliably measured or
reviewed the SFP diagnostic recordings, nor did this study display sta-
tistical analysis methods.Discussion
This meta-analysis estimates a high prevalence of SFP, with 49% of
people with ﬁbromyalgia having a structural abnormality of the small
nerve ﬁbers and to our knowledge this systematic literature review is
the ﬁrst study to collate data on the overall prevalence of SFP in ﬁbro-
myalgia. Based on the modiﬁed 2010 criteria, approximately 5% of
the population are affected by ﬁbromyalgia [53] and this equates to
around 1.6 million people with SFP and ﬁbromyalgia in the United
Kingdom alone. Fibromyalgia has major implications on morbidity
and patients experience a decline in their health-related quality of
life with a signiﬁcant economic burden on health services [54]. In our
review, small ﬁber pathology was deﬁned by objective tests which
were either by skin biopsy or corneal confocal microscopy, both of
which showed a high prevalence of SFP, challenging the current con-
cept that ﬁbromyalgia is largely a disorder of the CNS.biopsies. de Tommaso et al. [51]; Giannoccaro et al. [28]; Kosmidis et al. [30]; Leinders
Fig. 5. Forest plot showing prevalence estimates of SFP in ﬁbromyalgia in studies using CCM. Oudejans et al. [31] and Ramírez et al. [32].
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diagnosis of SFP in a priori inclusion criteria with our study conducted
to PRISMA guidelines [55]. The tests for statistical heterogeneity
amongst articles suggested signiﬁcant variability for overall pooled
data (I2 = 68%) and skin biopsy data (I2 = 70%) with moderate variabil-
ity in data from corneal confocal microscopy (I2 = 51%). Inconsisten-
cies in the classiﬁcation of a positive SFP diagnosis between studies
may have contributed to the high heterogeneity. In the study by de
Tommaso et al. [51], skin biopsies were undertaken in three loca-
tions; the thigh, distal leg and ﬁnger-tip. In contrast, Giannoccaro et
al. [28], Leinders et al. [52] and €Uc¸eyler et al. [26] obtained samples
from the thigh and distal leg, whilst Kosmidis et al. [30] and Oak-
lander et al. [27] obtained biopsies from the distal leg only. de Tom-
maso et al. [51], showed that 16/21 (76%) patients with ﬁbromyalgia
had an epidermal nerve density below the 5th percentile in at least
one site from the leg, thigh or ﬁngertip. Uceyler et al. [26] showed a
reduction in IENFD and regenerating nerves stained using GAP43 in
both the thigh and distal leg of 24 patients with ﬁbromyalgia. These
inconsistencies may limit the reliability of the prevalence estimate
and future standardised cut-off values for abnormal IENFD and in par-
ticular corneal nerve parameters in ﬁbromyalgia are warranted and
will allow for direct comparison in any future prevalence studies.
Abnormal CNS processing is evidenced in a number of studies in
ﬁbromyalgia which have shown altered resting and stimulus-evoked
regional cerebral blood ﬂow in pain and altered emotional processing
regions such as the thalamus, somatosensory cortex, insula, and ante-
rior cingulate cortex [8, 56]. However, the reduction in grey matter
volume noted in ﬁbromyalgia patients may be indicative of secondary
alterations in central neuroplasticity accompanying affective disor-
ders [57]. Indeed in ‘classical’ SFN, brain networks tend to alter and
deconstruct into functionally independent components (reduced
functional connectivity between the anterior cingulate cortex, amyg-
dala and praecuneus), with severity being linked to the degree of
cutaneous nerve degeneration [58]. In other pain syndromes such as
dysmenorrhoea, patients exhibit adaptive/reactive hyperconnectivity
within the sensorimotor cortex [59]. In neither of these conditions is
the primary pathological process in the CNS. The preponderance of
data regarding SFP supports the notion that besides central sensitisa-
tion, structural abnormalities of C-ﬁbers and altered C-ﬁber efferent
function might play a role in ﬁbromyalgia. In addition to reduced ﬁber
densities, in a study of 32 patients with ﬁbromyalgia there was evi-
dence of structural (reduced axon diameter of small nerve ﬁbers) and
functional (quantitative sensory testing) abnormalities in the small
ﬁbers [33].
Doppler et al. [33] also showed differences in the extent of small
ﬁber axonopathy compared to idiopathic SFP including a greater pro-
portion of ballooned Schwann cells, indicating different pathome-
chanisms [33]. Schwann cell ballooning and peripheral axonal
abnormalities have been demonstrated using electron microscopy in
the skin of people with ﬁbromyalgia [60]. Neurogenic inﬂammation
with involvement of C-ﬁbers is evidenced by inﬂammatory changes
in skin biopsies with IgG deposition in the dermis and vessel walls,
and the presence of tumour necrosis factor (TNF)-a and interleukin
(IL)¡6 [61, 62]. In an experimental model, a high fat diet sensitised
ﬁbromyalgia-like pain behaviours in mice via increased TNF-a [63].
There is also a link between obesity and ﬁbromyalgia and chronicpain [64, 65]. In a study of people with obesity and impaired glucose
tolerance with SFN, weight loss and exercise improved neuropathic
pain and IENFD [66]. Speciﬁc symptoms of dysautonomia and pares-
thesia, both of which are intimately related to small nerve ﬁber dys-
function may help identify underlying SFP in ﬁbromyalgia, as both
symptoms have some diagnostic utility (Area Under the Curve (AUC)
0.729) [67].
There remains considerable scepticism for the role of SFP [68],
despite the demonstration of signiﬁcant small nerve ﬁber dysfunction
and pathology in ﬁbromyalgia. Cutaneous small nerves generate pain
and connect to the CNS forming an integral part of pain processing
pathways, and small skin nerve ﬁber dysfunction and pathology have
been repeatedly demonstrated in ﬁbromyalgia. Nevertheless there
remains considerable scepticism about the relevance of these ﬁndings
for explaining the patients’ pain [51]; Indeed, it has been suggested
that some patients in whom ﬁbromyalgia is diagnosed are instead
affected by SFN with clinical features mimicking ﬁbromyalgia [69].
And in at least some patients, proximal ﬁber loss may be
greater than, or at least equal to, distal loss, conﬁguring a
nonlengthdependent pattern more compatible with the wide-
spread pain symptoms of ﬁbromyalgia [69]. An experimental study of
Sprague Dawley rats, suggested that increased insular glutamate was
associated with a reduction in IENFD [25], thus implying that a central
neurotransmitter defect may contribute to SFP. However, we suggest
caution in the translational value of an experiment with such small
numbers of animals to the human pathogenesis of SFP in ﬁbromyalgia
[25].
The peripheral origins of pain are not in doubt in painful neuropa-
thies, however, the question remains if central sensitization is the pri-
mary driver in ﬁbromyalgia. SFP also alters small blood vessel
function through altered neuropeptide response and upregulation of
a-adrenergic receptors [70]. This neurogenic microvasculopathy may
explain at least partially, the skeletal muscle perfusion deﬁcits, deep
pain, and exercise intolerance characteristic of ﬁbromyalgia and a
number of other small ﬁber neuropathies [71, 72]. This microvascul-
opathy mediated by small nerve ﬁbers may also contribute to the
common symptom of ‘brain fog’ and provide a putative mechanistic
link [73].
There was a limited opportunity to investigate the sources of
heterogeneity due to the small number of studies included and
lack of recorded patient's characteristics, we therefore only com-
pleted a stratiﬁed analysis based on the diagnostic modality of SFP.
Our study was limited to published data and English language pub-
lications which may introduce respective bias. Furthermore, only a
single point assessment of small nerve ﬁbers was undertaken in
the included studies; however, small nerve ﬁbers degenerate and
regenerate [74, 75] and therefore may alter over time. Another lim-
itation of our review was that none of the studies included for
prevalence estimates were primarily designed to produce preva-
lence data and is reﬂected in the relatively small sample sizes in
the included studies (largest study, n = 47). Only one study [27]
performed a sample size calculation to ensure that adequate
numbers were recruited. Two studies recruited from a single cen-
tre, namely de Tommaso et al. [51] and Kosmidis et al. [30], thus
presence of population bias with an unrepresentative sample is a
distinct possibility.
R. Grayston et al. / Seminars in Arthritis and Rheumatism 48 (2019) 933940 939The pooled prevalence estimates were higher with CCM suggest-
ing it may be a more sensitive measure of SFP. CCM quantiﬁes early
axonal damage [43], reliably [44], with high sensitivity and speciﬁcity
[45, 48] and closely correlates to the loss of IENF [47, 48]. As CCM is a
rapid, reiterative, non-invasive imaging modality of small nerve ﬁbers
it may provide an ideal method to accurately deﬁne the prevalence of
SFP in large population studies. Larger dedicated prevalence studies
are required to augment this meta-analysis and accurately deﬁne the
contribution of SFP in ﬁbromyalgia. In particular, SFP prevalence in
ﬁbromyalgia needs to be determined stratiﬁed on the basis of dura-
tion of disease which will provide a signiﬁcant insight in the natural
history of this chronic pain condition.
Conclusion
Our meta-analysis shows that the prevalence of SFP in ﬁbromyal-
gia is 49%. Fibromyalgia and chronic pain has a huge negative impact
on quality of life and reduces the ability of our patients to work and
function. There needs to be a signiﬁcant improvement in the under-
standing of pain in ﬁbromyalgia and the relative contribution of SFP
in relation to pain needs to be established.
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